FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact

Center for Computational Systems Medicine
leaf

FusionGeneSummary

leaf

FusionProtFeature

leaf

FusionGeneSequence

leaf

FusionGenePPI

leaf

RelatedDrugs

leaf

RelatedDiseases

Fusion gene ID: 14503

FusionGeneSummary for GCG_GCG

check button Fusion gene summary
Fusion gene informationFusion gene name: GCG_GCG
Fusion gene ID: 14503
HgeneTgene
Gene symbol

GCG

GCG

Gene ID

2641

2641

Gene nameglucagonglucagon
SynonymsGLP-1|GLP1|GLP2|GRPPGLP-1|GLP1|GLP2|GRPP
Cytomap

2q24.2

2q24.2

Type of geneprotein-codingprotein-coding
Descriptionglucagonglicentin-related polypeptideglucagon-like peptide 1glucagon-like peptide 2preproglucagonglucagonglicentin-related polypeptideglucagon-like peptide 1glucagon-like peptide 2preproglucagon
Modification date2018052320180523
UniProtAcc

P01275

P01275

Ensembl transtripts involved in fusion geneENST00000418842, ENST00000375497, 
ENST00000418842, ENST00000375497, 
Fusion gene scores* DoF score2 X 2 X 1=43 X 3 X 3=27
# samples 23
** MAII scorelog2(2/4*10)=2.32192809488736log2(3/27*10)=0.15200309344505
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
Context

PubMed: GCG [Title/Abstract] AND GCG [Title/Abstract] AND fusion [Title/Abstract]

Functional or gene categories assigned by FusionGDB annotation
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID

check button Fusion gene information from three resources
(ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018))
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
Data typeSourceCancer typeSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChiTaRS3.1AW582982GCGchr2

163000677

+GCGchr2

162999782

-
* LD: Li Ding group's fusion gene list
  RV: Roel Verhaak group's fusion gene list
  ChiTaRs fusion database

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
intron-3UTRENST00000418842ENST00000418842GCGchr2

163000677

+GCGchr2

162999782

-
intron-intronENST00000418842ENST00000375497GCGchr2

163000677

+GCGchr2

162999782

-
intron-3UTRENST00000375497ENST00000418842GCGchr2

163000677

+GCGchr2

162999782

-
intron-intronENST00000375497ENST00000375497GCGchr2

163000677

+GCGchr2

162999782

-

Top

FusionProtFeatures for GCG_GCG


check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
GCG

P01275

GCG

P01275

Glucagon plays a key role in glucose metabolism andhomeostasis. Regulates blood glucose by increasing gluconeogenesisand decreasing glycolysis. A counterregulatory hormone of insulin,raises plasma glucose levels in response to insulin-inducedhypoglycemia. Plays an important role in initiating andmaintaining hyperglycemic conditions in diabetes. GLP-1 is a potent stimulator of glucose-dependentinsulin release. Play important roles on gastric motility and thesuppression of plasma glucagon levels. May be involved in thesuppression of satiety and stimulation of glucose disposal inperipheral tissues, independent of the actions of insulin. Havegrowth-promoting activities on intestinal epithelium. May alsoregulate the hypothalamic pituitary axis (HPA) via effects on LH,TSH, CRH, oxytocin, and vasopressin secretion. Increases isletmass through stimulation of islet neogenesis and pancreatic betacell proliferation. Inhibits beta cell apoptosis. GLP-2 stimulates intestinal growth and up-regulatesvillus height in the small intestine, concomitant with increasedcrypt cell proliferation and decreased enterocyte apoptosis. Thegastrointestinal tract, from the stomach to the colon is theprincipal target for GLP-2 action. Plays a key role in nutrienthomeostasis, enhancing nutrient assimilation through enhancedgastrointestinal function, as well as increasing nutrientdisposal. Stimulates intestinal glucose transport and decreasesmucosal permeability. Oxyntomodulin significantly reduces food intake.Inhibits gastric emptying in humans. Suppression of gastricemptying may lead to increased gastric distension, which maycontribute to satiety by causing a sensation of fullness. Glicentin may modulate gastric acid secretion and thegastro-pyloro-duodenal activity. May play an important role inintestinal mucosal growth in the early period of life. Glucagon plays a key role in glucose metabolism andhomeostasis. Regulates blood glucose by increasing gluconeogenesisand decreasing glycolysis. A counterregulatory hormone of insulin,raises plasma glucose levels in response to insulin-inducedhypoglycemia. Plays an important role in initiating andmaintaining hyperglycemic conditions in diabetes. GLP-1 is a potent stimulator of glucose-dependentinsulin release. Play important roles on gastric motility and thesuppression of plasma glucagon levels. May be involved in thesuppression of satiety and stimulation of glucose disposal inperipheral tissues, independent of the actions of insulin. Havegrowth-promoting activities on intestinal epithelium. May alsoregulate the hypothalamic pituitary axis (HPA) via effects on LH,TSH, CRH, oxytocin, and vasopressin secretion. Increases isletmass through stimulation of islet neogenesis and pancreatic betacell proliferation. Inhibits beta cell apoptosis. GLP-2 stimulates intestinal growth and up-regulatesvillus height in the small intestine, concomitant with increasedcrypt cell proliferation and decreased enterocyte apoptosis. Thegastrointestinal tract, from the stomach to the colon is theprincipal target for GLP-2 action. Plays a key role in nutrienthomeostasis, enhancing nutrient assimilation through enhancedgastrointestinal function, as well as increasing nutrientdisposal. Stimulates intestinal glucose transport and decreasesmucosal permeability. Oxyntomodulin significantly reduces food intake.Inhibits gastric emptying in humans. Suppression of gastricemptying may lead to increased gastric distension, which maycontribute to satiety by causing a sensation of fullness. Glicentin may modulate gastric acid secretion and thegastro-pyloro-duodenal activity. May play an important role inintestinal mucosal growth in the early period of life.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page

.

* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note


Top

FusionGeneSequence for GCG_GCG


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences.
(nt: nucleotides, aa: amino acids)

* Fusion amino acid sequences.

* Fusion transcript sequences (only coding sequence (CDS) region).

* Fusion transcript sequences (Full-length transcript).

Top

FusionGenePPI for GCG_GCG


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page

.

check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

RelatedDrugs for GCG_GCG


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.0 2018-04-02)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status

Top

RelatedDiseases for GCG_GCG


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneGCGC0428977Bradycardia5CTD_human
HgeneGCGC0020456Hyperglycemia2CTD_human
HgeneGCGC0020649Hypotension2CTD_human
HgeneGCGC0007370Catalepsy1CTD_human
HgeneGCGC0009319Colitis1CTD_human
HgeneGCGC0009375Colonic Neoplasms1CTD_human
HgeneGCGC0009421Comatose1CTD_human
HgeneGCGC0009806Constipation1CTD_human
HgeneGCGC0011860Diabetes Mellitus, Non-Insulin-Dependent1CTD_human
HgeneGCGC0018799Heart Diseases1CTD_human
HgeneGCGC0018801Heart failure1CTD_human
HgeneGCGC0020459Hyperinsulinism1CTD_human
HgeneGCGC0020473Hyperlipidemia1CTD_human
HgeneGCGC0020538Hypertensive disease1CTD_human
HgeneGCGC0020672Hypothermia, natural1CTD_human
HgeneGCGC0028754Obesity1CTD_human
HgeneGCGC0037763Spasm1CTD_human
HgeneGCGC0038354Stomach Diseases1CTD_human
HgeneGCGC0039231Tachycardia1CTD_human
HgeneGCGC0039239Sinus Tachycardia1CTD_human
HgeneGCGC0042373Vascular Diseases1CTD_human
HgeneGCGC0424295Hyperactive behavior1CTD_human
HgeneGCGC1879526Aberrant Crypt Foci1CTD_human
TgeneGCGC0428977Bradycardia5CTD_human
TgeneGCGC0020456Hyperglycemia2CTD_human
TgeneGCGC0020649Hypotension2CTD_human
TgeneGCGC0007370Catalepsy1CTD_human
TgeneGCGC0009319Colitis1CTD_human
TgeneGCGC0009375Colonic Neoplasms1CTD_human
TgeneGCGC0009421Comatose1CTD_human
TgeneGCGC0009806Constipation1CTD_human
TgeneGCGC0011860Diabetes Mellitus, Non-Insulin-Dependent1CTD_human
TgeneGCGC0018799Heart Diseases1CTD_human
TgeneGCGC0018801Heart failure1CTD_human
TgeneGCGC0020459Hyperinsulinism1CTD_human
TgeneGCGC0020473Hyperlipidemia1CTD_human
TgeneGCGC0020538Hypertensive disease1CTD_human
TgeneGCGC0020672Hypothermia, natural1CTD_human
TgeneGCGC0028754Obesity1CTD_human
TgeneGCGC0037763Spasm1CTD_human
TgeneGCGC0038354Stomach Diseases1CTD_human
TgeneGCGC0039231Tachycardia1CTD_human
TgeneGCGC0039239Sinus Tachycardia1CTD_human
TgeneGCGC0042373Vascular Diseases1CTD_human
TgeneGCGC0424295Hyperactive behavior1CTD_human
TgeneGCGC1879526Aberrant Crypt Foci1CTD_human